Fig. 2
Clarithromycin interferes with the common pathway of labor. A Dams were intra-amniotically injected with HMGB1 under ultrasound guidance on 14.5 days post coitum (dpc) and treated with 75 mg/kg of clarithromycin (CLR; n = 7) or DMSO (vehicle control; n = 8) at 6, 12, 24, 48, 72, and 96 h post-injection. On 18.5 dpc, two hours after the last dose of CLR or DMSO, mice were euthanized and tissue collection was performed to obtain the decidua, uterus, cervix, fetal membranes, placenta, fetal lung, fetal intestine, fetal liver, and fetal spleen. Expression (-ΔCT) of B Oxtr, C Il1a, D Il1b, and E Ifng in the uteri of HMGB1-injected dams treated with CLR (blue dots) or DMSO (red dots). Expression (-ΔCT) of F Gja1 and G Mmp9 in the cervices of HMGB1-injected dams treated with CLR (blue dots) or DMSO (red dots). Expression (-ΔCT) of H Nfkb2 and I Casp11 in the fetal membranes of neonates born to HMGB1-injected dams treated with CLR (blue dots) or DMSO (red dots). Expression (-ΔCT) of J Il1a, K Il12b, L Ccl22, M Il10, N Ptgs2, and O Oxtr in the decidua of HMGB1-injected dams treated with CLR (blue dots) or DMSO (red dots). Data are represented as box-and-whisker plots with medians, interquartile ranges, and min/max ranges. P-values were determined using the one-sided Mann–Whitney U-test